Tag: retinitis-pigmentosa

2 articles

Industry News

Science Corp reports first sign PRIMA works in an inherited eye disease

Science Corporation said on 13 October 2026 that the first patient with Stargardt disease, a rare inherited cause of central vision loss, to receive its PRIMA retinal implant saw a letter in his first rehabilitation session and read a word in his second. It is the first clinical result Science has reported from PRIMA outside geographic atrophy, the form of age-related macular degeneration the implant is sold for in Europe and the UK. The claim rests on one patient and a company video, with no acuity data or publication.

Oct 15

Industry News

Nobel laureate Karl Deisseroth says light-based brain-computer interfaces will take a little time to build

Karl Deisseroth of Stanford University and the Howard Hughes Medical Institute shares the 2026 Nobel Prize in Physiology or Medicine, announced on 5 October, with Peter Hegemann of Humboldt University of Berlin and Georg Nagel of the University of Würzburg for discoveries concerning light-gated ion channels and optogenetics, the method of making chosen nerve cells switch on or off in response to light. Asked what the work means for neurotechnology devices, Deisseroth said brain-computer interfaces mostly run on electricity, recording activity and in some cases stimulating it, and that light could in principle do the same job but probably will take a little time to build. Optogenetics is closer to patients in two other forms. The FDA has accepted Nanoscope Therapeutics' application for MOGENRY, a one-time optogenetic eye injection for adults with retinitis pigmentosa and severe vision loss, with a decision expected in the first half of 2027. MapLight Therapeutics, which Deisseroth co-founded in 2018, plans a Phase 3 trial of a schizophrenia drug whose development drew on optogenetic laboratory work.

Oct 7